
Xencor (XNCR) Stock Forecast & Price Target
Xencor (XNCR) Analyst Ratings
Bulls say
Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. Their pipeline includes multiple promising candidates for cancer and autoimmune diseases, and they have a strong history of collaboration and licensing agreements to support their revenue. While there are inherent clinical, competitive, and financial risks, Xencor's diversified set of catalysts and a strong cash position suggest a positive outlook for the company's future growth and success.
Bears say
Xencor is facing significant de-risking with XMAB942's potential success in HS and SYRE's positive read-through on XMAB072's ability to achieve stat-sig improvement in ACR50. With first data from the XENITH-UC trial expected in 2H27 and multiple potential upside drivers from bispecific candidate XmAb412, plamotamab, and XmAb659, Xencor remains well-positioned for success in the biopharmaceutical market. Additionally, the upcoming Phase 1 expansion data update for XmAb819 inccRCC at ESMO in October adds even more potential for success in the near-term.
This aggregate rating is based on analysts' research of Xencor and is not a guaranteed prediction by Public.com or investment advice.
Xencor (XNCR) Analyst Forecast & Price Prediction
Start investing in Xencor (XNCR)
Order type
Buy in
Order amount
Est. shares
0 shares